UNIVERSITY HOSPITAL CONSORTIUM WILL SOLICIT BIDS FROM MFRS. FOR OVER 75 MULTI-SOURCE INJECTABLE PRODUCTS; WHSLR. BIDS WILL BE SOUGHT LATER
A drug purchasing consortium of university hospitals will soon begin soliciting competitive bids from manufacturers for over 75 multi-source injectable hospital products. The solicitation will be the first ever by University Hospital Consortium, a group which includes 39 university hospitals in 27 states with headquarters in Atlanta. The bid solicitation will go out within "the next week or two," according to UHC Director of Pharmacy Purchasing William Hinshaw. At the same time, the group will begin negotiating with the manufacturers of approximately 100 single source products. Among the multi-source products for which bids will be accepted are: ampicillin, cafazolin, cyclophosphamide, heparin, and methylprednisolone. The group is using a two-tiered bid program, in which manufacturers are being solicite dinitially, Hinshaw said. After manufacturer bids are handled, the group will then make a new bid solicitation to drug whslrs. Among the members of the consortium are university owned or affiliated hospitals at Stanford, UCLA, University of Michigan, New York University, and the University of Colorado. The consortium was incorporated as a purchasing organization in October 1984, after being established in 1980 as the Consortium for the Study of University Hospitals. That earlier form of the group existed to study particular issues in the administration of university hospitals, and to determine ways in which such institutions could be cooperatively linked. UHC is considering expanding its functions in the future. The organization said it was planning to conduct a feasibility study to evaluate a possible investigational drug management program. Under such a program, mfrs. would contract physicians from UHC to investigate particular drug products. UHC is also considering a drug information program, whereby it would serve as a conduit for information on drugs being considered for hospital formularies. UHC noted that currently when a drug is considered for a hospital formulary, each hospital pharmacy therapeutics cmte. reviews the drug, a process which UHC said costs in excess of $1,000 in each case.
Sign in to continue reading.
New to Pink Sheet?
Start a free trial today!
Register for our free email digests: